Wall Street analysts expect Agilent Technologies (A) to post quarterly earnings of $1.19 per share in its upcoming report, which indicates a year-over-year decline of 6.3%. Revenues are expected to be $1.58 billion, down 8% from the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Prior to a company's earnings announcem ...

Product Innovation - Agilent Technologies introduces the 8850 Gas Chromatograph (GC) System, a compact single-channel GC that combines the legacy of the 6850 GC with the capabilities of the 8890 GC [1] - The 8850 GC is designed to revolutionize labs across diverse markets including energy, chemicals, food, and pharmaceuticals [1] - The new GC system reduces energy consumption by up to 30% compared to other GCs [1][2] Technological Advancements - The 8850 GC leverages the latest technological advancements, incorporating engineering excellence and the intelligence of Agilent's smart GC portfolio [2] - Integrated instrument intelligence enhances uptime, while remote connectivity features facilitate regular maintenance and troubleshooting [2] - The instrument's small footprint is half the size of the Agilent 8890 GC, maximizing space utilization and operational redundancy [2] Operational Efficiency - The 8850 GC offers shorter heating and cool-down times, increasing lab throughput [2] - The instrument uses up to 30% less power than other GCs, reducing energy costs and helping labs meet sustainability goals [2] - The 8850 GC uses the same touchscreen interface and connectivity as the 8890 GC, minimizing method migration and development efforts [3] Market Impact - The 8850 GC is a powerful addition to Agilent's market-leading portfolio of GC instruments, promising to transform lab operations with its reliability, high performance, and exceptional data quality [3] - The instrument is designed to meet the needs of modern labs, which face the challenge of maximizing analytical capacity with limited bench space while reducing environmental impact [1] Company Overview - Agilent Technologies is a global leader in analytical and clinical laboratory technologies, generating revenue of $6 83 billion in fiscal 2023 and employing approximately 18,000 people worldwide [4] - The company offers a full range of solutions including instruments, software, services, and expertise to address customers' most challenging questions [4]

The market expects Agilent Technologies (A) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended April 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be relea ...

Core Insights - Agilent Technologies has a strong history of beating earnings estimates and is well-positioned for future earnings growth [1][2] - The company has surpassed earnings estimates by an average of 4.80% over the last two quarters, with a recent surprise of 6.61% [1] - Agilent's Earnings ESP is currently +0.72%, indicating a positive outlook from analysts [3] Group 1: Earnings Performance - Agilent reported earnings of $1.29 per share for the most recent quarter, exceeding the expected $1.21 per share [1] - In the previous quarter, Agilent's actual earnings were $1.38 per share, surpassing the consensus estimate of $1.34 per share [1] - The company has a strong track record of earnings surprises, with a positive Earnings ESP suggesting potential for continued success [2][3] Group 2: Analyst Sentiment - Recent estimates for Agilent have been revised upward, reflecting increased analyst confidence in the company's earnings prospects [2][3] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) indicates a high likelihood of another earnings beat [2][3] - Stocks with a positive Earnings ESP and a favorable Zacks Rank have historically produced positive surprises nearly 70% of the time [2]

Agilent Technologies (A) is set to showcase a slew of new products at Analytica 2024, to be held between Apr 9 and Apr 12.The company will showcase its newly upgraded BioTek Cytation C10 Confocal Imaging Reader, featuring water immersion and confocal spinning-disk technologies for improved image quality, minimized effects on live-cell samples, and enhanced clarity for thicker samples. Agilent will also showcase Advanced Dilution System (ADS 2).Additionally, the Agilent 1290 Infinity II Bio Online LC Solutio ...

Agilent Technologies (A) has announced its plans to introduce new cell analysis, genomics, digital pathology and companion diagnostics solutions to highlight its advancement in cancer research and diagnostics at the American Association for Cancer Research Annual Meeting.This includes Agilent NovoCyte Opteon Spectral Flow Cytometer, a user-friendly, advanced spectral flow cytometry system with multiple marker panels and up to 70 detectors, enhancing cancer research capabilities.Further, the company will als ...

Core Insights - Agilent Technologies has launched the Advanced Dilution System (ADS) 2 to improve auto-dilution adoption and enhance laboratory workflow efficiency [1] - The global analytical instrumentation market is projected to reach $66.3 billion by 2028, with a CAGR of 6% from 2023 to 2028, presenting growth opportunities for Agilent [1] Segment Focus - The new product launch aligns with Agilent's strategy to strengthen its Life Sciences & Applied Markets Group (LSAG) segment [2] - At the HPLC Conference 2023, Agilent showcased its expanded InfinityLab GPC/SEC Solution and other advanced systems, indicating a focus on material characterization [2] - A Memorandum of Understanding was signed with the Sarawak Infectious Disease Centre to provide the 6475 triple quadrupole LC/MS system for research on neglected tropical diseases, enhancing the LSAG segment's clientele [2] Financial Performance - The LSAG segment is expected to positively impact Agilent's financial performance in the near term, despite facing challenges from sluggish capital equipment spending [3] - Agilent's shares have increased by 4.7% year-to-date, underperforming the Zacks Computer & Technology sector's growth of 12.2% [3] - The Zacks Consensus Estimate for Q2 fiscal 2024 total revenues is $1.58 billion, reflecting a year-over-year decline of 7.8%, while earnings are expected to be $1.19 per share, down 6.3% year-over-year [3]

Core Insights - Zacks offers a curated Focus List of 50 stocks aimed at long-term investors, expected to outperform the market over the next 12 months [2] - The Focus List has demonstrated strong past performance, with a cumulative return of 2,519.23% from February 1, 1996, to March 31, 2021, compared to the S&P 500's return of 854.95% [3] - The methodology for selecting stocks in the Focus List relies on earnings estimate revisions, which are critical for predicting future growth and profitability [4] Focus List Performance - In 2020, the Focus List gained 13.85% on an annualized basis, outperforming the S&P 500's return of 9.38% [3] - The stocks in the Focus List are selected based on a proprietary Zacks Rank model, which evaluates changes in quarterly earnings expectations [5] Stock Selection Criteria - Stocks are chosen based on positive changes to earnings estimates, indicating potential for future upward revisions and price momentum [6] - The Zacks Rank categorizes stocks into five groups, with the Focus List primarily consisting of 1 (Strong Buy) and 2 (Buy) ranked companies [5] Spotlight on Agilent Technologies - Agilent Technologies was added to the Focus List at $59.86 per share and has since increased by 143.08% to $145.51 [7] - For fiscal 2024, Agilent's earnings estimate has been revised upwards by five analysts, with the Zacks Consensus Estimate increasing by $0.03 to $5.51 [7] - Agilent's earnings are projected to grow by 1.3% for the current fiscal year [7]

Core Points - Agilent Technologies Inc. announced the 2024 Darlene Solomon Award recipient, Joycelyn Tan, a Ph.D. student at the University of Cambridge, recognizing her contributions to mass spectrometry research [1][2] - The award aims to support promising female scientists in mass spectrometry and includes opportunities for professional development and exposure to industry-leading technologies [3][4] Company Overview - Agilent Technologies is a global leader in analytical and clinical laboratory technologies, generating revenue of $6.83 billion in fiscal 2023 and employing approximately 18,000 people worldwide [5] - The company is committed to fostering an inclusive environment for female scientists and supports initiatives like the Darlene Solomon Award to promote diversity in the field [2][3]

Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.The Zacks Premium service makes this easier. It features daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter. All of these can help you quickly identify what stocks to buy, what to sell, and what are today's hottest ...